


GLOBAL NEWS

Vivaldis Animal Health : World's Top Animal Health Companies Enhancing Lives¹

Insights Success



Vivaldis has always focused on providing innovative and path breaking treatment options in the field of companion animal healthcare. Our commitment to pet welfare is one of the many reasons why we are amongst the World's Top Animal Health Companies Enhancing Lives published by Insights Success.

Mr. Kunal Khanna, CEO & Founder of Vivaldis talks about Veterinary care, journey of Vivaldis, future plans and much more. Link to the article is provided on our social media accounts.

Complications associated with and outcome of surgical intervention for treatment of esophageal foreign bodies in dogs²

AVMA, January 4th 2022

In a recent study To identify complications associated with and short- and long-term outcomes of surgical intervention for treatment of esophageal foreign bodies (EFBs) in dogs, it was found that 54 of the 63 (85.7%) dogs underwent surgery after an unsuccessful minimally invasive procedure or subsequent evidence of esophageal perforation was identified. Esophageal perforation was present at the time of surgery in 42 (66.7%) dogs. Most dogs underwent a left intercostal thoracotomy (37/63 [58.7%]). Intraoperative complications occurred in 18 (28.6%) dogs, and 28 (50%) dogs had a postoperative complication. Postoperative complications were minor in 14 of the 28 (50%) dogs. Dehiscence of the esophagotomy occurred in 3 dogs. Forty-seven (74.6%) dogs survived to discharge. Presence of esophageal perforation preoperatively, undergoing a thoracotomy, and whether a gastrostomy tube was placed were significantly associated with not surviving to discharge. Follow-up information was available for 38 of 47 dogs (80.9%; mean follow-up time, 46.5 months). Infrequent vomiting or regurgitation was reported by 5 of 20 (25%) owners, with 1 dog receiving medication.

Results suggested that surgical management of EFBs can be associated with a high success rate. Surgery should be considered when an EFB cannot be removed safely with minimally invasive methods or esophageal perforation is present.

VIVALDIS CORNER

Vivaldis launches Pancresolve, Enzymatic therapy for Exocrine Pancreatic Insufficiency (EPI)

PANCRESOLVE



Presentation: Each box contains 10 strips of 10 tablets

Dosage

For Dogs: 2 – 3 tablets before every meal
For Cats: ½ to 1 tablet before every meal

Tablets need to be given 15 to 20 minutes before meal.
Tablets can be given whole or crushed.

ARTICLE

Pancrelipase Therapy

(Pubmed, January 2022)

Pancrelipase, a combination of lipase, protease, and amylase, has benefited patients with exocrine pancreatic insufficiency. The FDA-approved conditions that are associated with pancreatic insufficiency that may require supplementation with pancrelipase include chronic pancreatitis, obstructive pancreatic tumors, post-procedure loss of pancreatic tissue or ductal occlusion, insufficient mixing of chyme with pancreatic enzymes because of rapid gastric emptying, small bowel resection with inadequate secretion of cholecystokinin-pancreozymin and secretin, and lymph node dissection leading to decreased pancreatic stimulation. Also approved are genetic disorders including cystic fibrosis, Schwachman Diamond syndrome, hereditary hemochromatosis, Zollinger-Ellison syndrome, celiac disease, and Crohn disease. There are also non-FDA-approved indications as well. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of pancrelipase so providers can direct patient therapy to optimal outcomes in conditions where pancrelipase has benefit.

Stay connected with

[facebook.com/vivaldisanimalhealth](https://www.facebook.com/vivaldisanimalhealth) | [instagram.com/vivaldisanimalhealth](https://www.instagram.com/vivaldisanimalhealth) | [linkedin.com/company/vivaldisanimalhealth](https://www.linkedin.com/company/vivaldisanimalhealth)